title: Tetra-arsenic oxide (Tetras) enhances radiation sensitivity of solid tumors by anti-vascular effect.
abstract: Tetras (tetra-arsenic oxide, As(4)O(6)) is a derivative of arsenic used in Korean traditional medicine for the treatment of cancer, but its mechanism remains largely undefined. Recently, a similar arsenic derivative, diarsenic trioxide (As(2)O(3), ATO), has been shown to mediate anti-tumor activity, therefore reigniting interest in the therapeutic effect of arsenic compounds. Here we report that Tetras can effectively mediate an anti-vascular effect on tumors, leading to delay in tumor growth and increased survival. Our study demonstrates for the first time the potential use of Tetras as a radiation therapy enhancement agent for solid tumors. These findings reveal an unappreciated role of Tetras in cancer therapy and its potential application to radiotherapy in achieving local tumor control.
authors.affiliation: Department of Microbiology, Busanpaik Hospital, Inje University College of Medicine, 633-165 Gaegum-Dong, Jin-Gu, Busan, Republic of Korea. micpsg@inje.ac.kr
authors.forename: Sae-Gwang
authors.initials: SG
authors.lastname: Park
authors.forename: Jeong-Joo
authors.initials: JJ
authors.lastname: Jung
authors.forename: Hae Jeong
authors.initials: HJ
authors.lastname: Won
authors.forename: Mi Seon
authors.initials: MS
authors.lastname: Kang
authors.forename: Su-Kil
authors.initials: SK
authors.lastname: Seo
authors.forename: Il-Whan
authors.initials: IW
authors.lastname: Choi
authors.forename: Choong Ki
authors.initials: CK
authors.lastname: Eun
authors.forename: Ki Jung
authors.initials: KJ
authors.lastname: Ahn
authors.forename: Cheol Woo
authors.initials: CW
authors.lastname: Park
authors.forename: Soo-Woong
authors.initials: SW
authors.lastname: Lee
authors.forename: Young S
authors.initials: YS
authors.lastname: Lew
authors.forename: Ill-Ju
authors.initials: IJ
authors.lastname: Bae
authors.forename: In-Hak
authors.initials: IH
authors.lastname: Choi
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009303:Nasopharyngeal Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000532:radiotherapy*; D009368:Neoplasm Transplantation; D018307:Neoplasms, Squamous Cell / Q000098:blood supply / Q000188:drug therapy* / Q000532:radiotherapy*; D010087:Oxides / Q000627:therapeutic use*; D011836:Radiation Tolerance / Q000187:drug effects*; D014183:Transplantation, Heterologous
chemical_list: D020533:Angiogenesis Inhibitors; D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide